Wide Ranks

CMRX

Chimerix, Inc.

0.9050

Top Statistics
Market Cap 81 M Forward PE -0.7904 Revenue Growth 136.40 %
Current Ratio 6.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.5840 Enterprise / Revenue -340.84 Price To Sales Trailing12 Months 511.90
Profitability
Profit Margins 0.00 % Operating Margins -95357.70 %
Balance Sheet
Total Cash 136 M Total Cash Per Share 1.51 Total Debt 644000
Total Debt To Equity 0.4740 Current Ratio 6.33 Book Value Per Share 1.51
All Measures
Short Ratio 274.00 % Message Board Id finmb_3280635 Fax 919 806 1146
Shares Short Prior Month 1 M Return On Equity -0.4859 City Durham
Uuid 7389e162-7c43-3cdb-be64-0bc435a74d1a Previous Close 0.9041 First Trade Date Epoch Utc 1 B
Book Value 1.51 Beta 1.13 Total Debt 644000
Volume 78301 Price To Book 0.5993 Fifty Two Week Low 0.7500
Total Cash Per Share 1.51 Total Revenue 159000 Shares Short Previous Month Date 1 B
Target Median Price 6.00 Max Age 86400 Recommendation Mean 1.20
Sand P52 Week Change 0.3133 Operating Margins -95357.70 % Target Mean Price 7.00
Net Income To Common -83594000 Short Percent Of Float 0.0083 Implied Shares Outstanding 89 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 211730
Average Volume10days 211730 Total Cash 136 M Next Fiscal Year End 1 B
Revenue Per Share 0.0020 Held Percent Insiders 0.0663 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.9041
Target Low Price 5.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.9084
Open 0.9000 Free Cashflow -40054624 State NC
Dividend Yield 0.00 % Return On Assets -0.3022 Time Zone Short Name EST
Trailing Eps -0.9400 Day Low 0.9000 Address1 2505 Meridian Parkway
Shares Outstanding 89 M Price Hint 4 Target High Price 11.00
Website https://www.chimerix.com 52 Week Change -0.0619 Average Volume 193334
Forward Eps -1.03 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 613.10 % Is_sp_500 False Regular Market Day High 0.9357
Profit Margins 0.00 % Debt To Equity 0.4740 Fifty Two Week High 1.30
Day High 0.9357 Shares Short 710246 Regular Market Open 0.9000
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -340.84
Revenue Growth 136.40 % Shares Percent Shares Out 0.0079 Operating Cashflow -70297000
Currency USD Time Zone Full Name America/New_York Market Cap 81 M
Is_nasdaq_100 False Zip 27713 Quote Type EQUITY
Industry Biotechnology Long Name Chimerix, Inc. Regular Market Day Low 0.9000
Held Percent Institutions 0.4590 Current Price 0.9050 Address2 Suite 100
Enterprise To Ebitda 0.5840 Financial Currency USD Current Ratio 6.33
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 75 M Two Hundred Day Average 0.9515 Enterprise Value -54193872
Price To Sales Trailing12 Months 511.90 Forward PE -0.7904 Regular Market Volume 78301
Ebitda -92735000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.

Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox.

Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.